IL300547A - Microsphere formulations comprising ketamine and methods for their production and use - Google Patents

Microsphere formulations comprising ketamine and methods for their production and use

Info

Publication number
IL300547A
IL300547A IL300547A IL30054723A IL300547A IL 300547 A IL300547 A IL 300547A IL 300547 A IL300547 A IL 300547A IL 30054723 A IL30054723 A IL 30054723A IL 300547 A IL300547 A IL 300547A
Authority
IL
Israel
Prior art keywords
polymer
microsphere
ketamine
microspheres
polymer microspheres
Prior art date
Application number
IL300547A
Other languages
English (en)
Hebrew (he)
Inventor
GALASKA Rachel
KAHT Kelsey
Richey Tracy
Original Assignee
Oakwood Laboratories LLC
GALASKA Rachel
KAHT Kelsey
Richey Tracy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC, GALASKA Rachel, KAHT Kelsey, Richey Tracy filed Critical Oakwood Laboratories LLC
Publication of IL300547A publication Critical patent/IL300547A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
IL300547A 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for their production and use IL300547A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067068P 2020-08-18 2020-08-18
US202163149911P 2021-02-16 2021-02-16
PCT/US2021/046220 WO2022040130A1 (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for making and using the same

Publications (1)

Publication Number Publication Date
IL300547A true IL300547A (en) 2023-04-01

Family

ID=80270269

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300547A IL300547A (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for their production and use

Country Status (10)

Country Link
US (1) US12233165B2 (https=)
EP (1) EP4199917B1 (https=)
JP (1) JP7814375B2 (https=)
KR (1) KR20230052915A (https=)
CN (1) CN115942935B (https=)
AU (1) AU2021329820A1 (https=)
CA (1) CA3191160A1 (https=)
IL (1) IL300547A (https=)
TW (1) TWI906350B (https=)
WO (1) WO2022040130A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
EP4611729A1 (en) * 2022-10-31 2025-09-10 Oakwood Laboratories, LLC Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU6510400A (en) 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
US6479007B1 (en) 1999-09-16 2002-11-12 University Technology Corporation Apparatus and method for controlling pore size in polymeric membranes and thin films
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1387671A1 (en) * 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
WO2005107714A2 (en) 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
KR101271263B1 (ko) 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
CA2635374C (en) 2006-01-11 2015-12-08 Hyperbranch Medical Technology, Inc. Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US20070292521A1 (en) * 2006-06-20 2007-12-20 Schwitzer Co., Ltd Oral Encapsulated Preparation for Aquatic Animals
US20110027331A1 (en) 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
WO2013119183A1 (en) 2012-02-06 2013-08-15 Nanyang Technological University Methods of manufacturing core-shell microparticles, and microparticles formed thereof
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2017075136A1 (en) 2015-10-27 2017-05-04 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
SG11202001206YA (en) 2017-09-14 2020-03-30 Agency Science Tech & Res Emulsions, methods and uses thereof
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
EP3968979A4 (en) 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
EP3993898B1 (en) 2019-07-01 2025-10-15 Oakwood Laboratories, Llc System and method for making microspheres and emulsions
US20220401366A1 (en) * 2019-11-15 2022-12-22 Consegna Pharma, Inc. Long acting nmda antagonists
PH12022550775A1 (en) 2019-12-20 2023-08-23 Alar Pharmaceuticals Inc Long-acting injectable formulations of ketamine pamoate salts
US20210361578A1 (en) 2020-04-03 2021-11-25 University Of Iowa Research Foundation Mek1/2 inhibitor-loaded microparticle formulation

Also Published As

Publication number Publication date
TWI906350B (zh) 2025-12-01
TW202227044A (zh) 2022-07-16
CA3191160A1 (en) 2022-02-24
EP4199917C0 (en) 2026-01-07
EP4199917A4 (en) 2024-10-30
US12233165B2 (en) 2025-02-25
EP4199917B1 (en) 2026-01-07
WO2022040130A1 (en) 2022-02-24
US20220054420A1 (en) 2022-02-24
CN115942935A (zh) 2023-04-07
JP2023538901A (ja) 2023-09-12
EP4199917A1 (en) 2023-06-28
JP7814375B2 (ja) 2026-02-16
AU2021329820A1 (en) 2023-03-09
CN115942935B (zh) 2025-09-05
KR20230052915A (ko) 2023-04-20

Similar Documents

Publication Publication Date Title
IL269205A (en) Solid amorphous dispersion for use in the treatment of a patient with lung cancer who responds positively to erbb2
IL300547A (en) Microsphere formulations comprising ketamine and methods for their production and use
KR100946275B1 (ko) 수 난용성 캄토테신 유도체의 미세 나노입자 및 그의제조방법
IL265260A (en) Pharmaceutical preparations
NZ533435A (en) Injectable depot compositions and uses thereof
NZ595388A (en) Pharmaceutical compositions of clonazepam and methods of use thereof
JP2016513721A (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
NZ551748A (en) Irinotecan formulation
WO2015075942A1 (ja) 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法
CN102949375B (zh) 一种盐酸小檗碱固体脂质纳米制剂及其制备方法
US20220183976A1 (en) Compositions of dispersed phase for preparation of apixaban-loaded microspheres and biocompatible polymer-based apixaban-loaded microspheres prepared therefrom
Bhanderi et al. Optimized rivastigmine nanoparticles coated with Eudragit for intranasal application to brain delivery: evaluation and nasal ciliotoxicity studies. Materials (Basel). 2021; 14 (21)
IL301221A (en) Pharmaceutical compositions comprising an antisense oligonucleotide for oral administration
Ingabire et al. Nor-LAAM loaded PLGA microparticles for treating opioid use disorder
IL273988B2 (en) Cannabidiol and chitosan compositions and methods of using the same
IL256504A (en) Solid pharmaceutical preparations for the treatment of hcv
IL322310A (en) Methods for treating multiple sclerosis complex
CN102293748B (zh) 一种口服聚乙二醇化胰岛素pH敏感纳米粒及其制备方法
JP5613396B2 (ja) 腸管吸収性を改善する医薬組成物
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
ES3061392T3 (en) Microsphere formulations comprising ketamine and methods for making and using the same
JP2024536879A5 (https=)
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20240342115A1 (en) Microsphere formulations comprising ketamine and methods formaking and using the same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same